N-myristoylation is an irreversible covalent lipid modification in which a 14-carbon myristoyl group is attached to the N-terminal glycine residue of proteins, regulating membrane targeting, signal transduction, and apoptosis. Reliable detection of N-myristoylation requires specialized chemical biology and mass spectrometry workflows, including metabolic labeling with clickable myristic acid analogs, click chemistry enrichment, and LC-MS/MS site mapping. This article presents a comprehensive technical overview of N-myristoylation modification detection, covering sample types, analytical methods, testing items, and applications in disease research and drug discovery.
Technical Overview
N-myristoylation is a fundamental eukaryotic protein lipidation event in which myristic acid (a saturated C14 fatty acid) is covalently attached through a stable amide bond to the alpha-amino group of an N-terminal glycine residue. The reaction is catalyzed by N-myristoyltransferase (NMT), a member of the GCN5-related N-acetyltransferase superfamily, using myristoyl-CoA as the acyl donor. In mammals, two isoforms, NMT1 and NMT2, are responsible for the modification of several hundred cellular substrates.
- Cotranslational pathway: the initiator methionine is removed by methionine aminopeptidase (MetAP), exposing a glycine residue that is myristoylated while the nascent chain is still associated with the ribosome.
- Post-translational pathway: proteolytic cleavage, most notably by caspases during apoptosis, can expose an internal glycine residue that becomes a substrate for NMT.
- Consensus motif: substrates typically conform to a GXXXS/T-type sequence at the N-terminus, where glycine at position 2 is absolutely required and serine or threonine is frequently found at positions 5 or 6.
- Chemical stability: because myristate is linked via an amide bond, the modification is resistant to hydroxylamine treatment, which distinguishes it from thioester-linked S-palmitoylation.
- Functional consequences: N-myristoylation promotes reversible membrane association, participates in myristoyl-switch mechanisms, modulates protein-protein interactions, and regulates protein stability and conformation.
Representative myristoylated proteins include Src-family kinases (Src, Fyn, Lyn, Lck, Yes), heterotrimeric G-protein alpha subunits (Gαi), ADP-ribosylation factors (ARFs), MARCKS, recoverin, eNOS, and numerous viral proteins such as HIV-1 Gag and Nef. Because dysregulated myristoylation is implicated in cancer, immune disorders, and infectious diseases, accurate analytical detection of this modification has become an essential capability in both basic research and pharmaceutical development.
Testing Samples
Cultured Cell Samples
Adherent or suspension mammalian cells are the most common sample type for N-myristoylation analysis. Cells are metabolically labeled in culture with fatty acid analogs prior to harvest, typically requiring 1×10⁷ to 2×10⁸ cells per experiment depending on the abundance of the target protein. Both endogenous proteins and ectopically expressed, epitope-tagged constructs can be analyzed.
Tissue Samples
Fresh-frozen animal tissues, tumor biopsies, and clinical specimens can be analyzed, although direct metabolic labeling is not feasible ex vivo. For such samples, detection relies on affinity enrichment strategies combined with LC-MS/MS or on immunoprecipitation of target proteins followed by targeted mass spectrometry. Approximately 50–200 mg of tissue is generally recommended.
Recombinant and Purified Proteins
Purified recombinant proteins, in vitro translation products, and immunoprecipitated endogenous proteins are suitable for targeted verification. These samples support both confirmatory analysis of a known myristoylation site and in vitro NMT enzymatic activity assays using myristoyl-CoA as the donor substrate.
Pathogen-Infected Samples
Lysates from virus-infected cells, bacteria expressing recombinant viral proteins, and parasite lysates (for example, Plasmodium falciparum, Trypanosoma brucei, and Leishmania species) are frequently submitted, since pathogen NMTs and their substrates are prominent antimicrobial and antiviral drug targets.
Testing Items
Our N-myristoylation detection platform supports a complete portfolio of analytical items, from single-protein verification to system-level myristoylome profiling:
- Confirmation of the myristoylation status of a specific protein of interest.
- Mapping of N-myristoylation sites, including N-terminal cotranslational sites and caspase-cleavage-generated internal glycine sites.
- Global qualitative profiling of the cellular myristoylome using clickable fatty acid probes and quantitative LC-MS/MS.
- Quantitative comparison of myristoylation levels across experimental conditions, disease states, or drug treatments using SILAC, TMT, or label-free quantification.
- NMT enzymatic activity assays and kinetic characterization using recombinant NMT1/NMT2 and myristoyl-CoA substrates.
- Evaluation of NMT inhibitors, dose-response studies, and cellular target-engagement analysis.
- Functional validation through glycine-to-alanine (G2A) mutagenesis controls and hydroxylamine sensitivity testing.
Testing Methods
Metabolic Labeling with Clickable Myristic Acid Analogs
The current gold-standard approach uses omega-alkynyl or omega-azido analogs of myristic acid, such as tetradec-13-ynoic acid (YnMyr) or 14-propargyloxy-tetradecanoic acid (Alk14). Living cells incorporate these probes into NMT substrates in place of natural myristate. Lysates are then subjected to copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azido- or alkynyl-biotin or fluorophores, enabling detection by in-gel fluorescence, streptavidin Western blotting, or streptavidin enrichment for downstream proteomics.
Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
High-resolution LC-MS/MS provides direct, unambiguous identification of myristoylated peptides. The myristoyl group adds a characteristic mass shift of approximately +210.198 Da to the N-terminal glycine, and fragmentation produces diagnostic low-mass immonium-type ions corresponding to the lipidated glycine terminus. Following streptavidin enrichment, on-bead digestion, and LC-MS/MS analysis, database searching with the defined N-terminal modification allows confident site localization and protein identification.
Hydroxylamine Resistance Assay
Treatment of samples with neutral hydroxylamine cleaves thioester-linked palmitate but leaves amide-linked myristate intact. This chemical discrimination is a critical control for confirming that the observed lipidation signal derives from N-myristoylation rather than S-palmitoylation, particularly when fatty acid analogs with overlapping chemistry are used.
Conventional Radiolabeling
Historically, metabolic labeling with tritiated myristic acid followed by fluorography or autoradiography was the standard method. Although highly specific, this approach suffers from low sensitivity, long exposure times, and radiological handling requirements, and it has largely been superseded by click chemistry and mass spectrometry workflows.
Essential Controls and Validation Strategy
Rigorous N-myristoylation detection requires a panel of orthogonal controls:
- NMT inhibition or knockdown: pharmacological inhibitors such as IMP-1082 or DDD85646, or siRNA/CRISPR-mediated depletion of NMT1/NMT2, confirms enzyme dependence.
- Elongation control: fatty acid chain elongation can convert short myristate analogs into palmitate analogs, generating false-positive palmitoylation signals; fatty acid elongase or synthase inhibitors such as cerulenin are used to suppress this conversion.
- Mutagenesis control: substitution of the acceptor glycine with alanine (G2A) should abolish the signal attributable to N-myristoylation.
- Hydroxylamine insensitivity: resistance to neutral hydroxylamine confirms amide-type linkage.
Applications
N-myristoylation detection services support a wide range of research and translational objectives:
- Oncology and kinase signaling: analysis of myristoylation-dependent membrane localization of Src-family kinases, BTK, and ABL, and characterization of oncogenic signaling rewiring in tumor cells.
- Apoptosis research: identification of caspase-triggered post-translational myristoylation on cleavage products of proteins such as BID, actin, and gelsolin, revealing hidden pro-apoptotic lipidation events.
- Host-pathogen interactions: profiling of viral myristoylated proteins (HIV-1 Gag and Nef, poliovirus VP4) and validation of parasite NMTs as therapeutic targets.
- Immunology: quantitative studies of myristoylated signaling proteins in T cells and B cells, including Lck, Fyn, and Gαi subunits, during activation and differentiation.
- Drug discovery: biochemical and cellular assays supporting NMT inhibitor programs, including compounds such as PCLX-001 that have advanced into clinical evaluation for hematological malignancies.
- Comparative myristoylomics: system-level comparison of the myristoylated proteome between healthy and diseased states, or before and after pharmacological intervention.
FAQ
How is N-myristoylation distinguished from S-palmitoylation during detection?
The two modifications differ chemically and can be separated experimentally. N-myristoylation is an amide linkage on an N-terminal glycine and is resistant to hydroxylamine, whereas S-palmitoylation is a thioester linkage on cysteine and is hydroxylamine-sensitive. In addition, NMT inhibition or G2A mutagenesis specifically abolishes myristoylation, and mass spectrometry directly identifies the modified glycine terminus with a +210.198 Da mass shift.
Why can metabolic labeling with myristate analogs sometimes overestimate myristoylation?
Short alkynyl fatty acid probes can be processed by cellular elongation machinery into C16 palmitate analogs that label palmitoylated proteins. This is controlled by co-treatment with elongation inhibitors such as cerulenin, by NMT dependency testing, and by confirming hydroxylamine resistance, ensuring the signal is genuinely attributable to N-myristoylation.
Can endogenous proteins be analyzed without overexpression?
Yes. When the target protein is sufficiently abundant, immunoprecipitation followed by click chemistry detection or targeted LC-MS/MS enables endogenous-level analysis. For low-abundance proteins, larger sample inputs or enrichment-based myristoylome workflows are recommended.
What are the typical sample requirements?
For cell-based click chemistry assays, 1×10⁷ to 2×10⁸ cells are typically sufficient. For tissue-derived samples, 50–200 mg of fresh-frozen material is recommended. Purified protein samples should be provided at microgram levels in detergent-free, amine-free buffers whenever possible to maximize labeling efficiency and MS compatibility.
What is the typical project workflow and turnaround time?
A standard project proceeds through experimental design consultation, metabolic labeling or sample preparation, click chemistry tagging, enrichment and detection, LC-MS/MS acquisition, and bioinformatic analysis with a full technical report. Typical turnaround is 3–6 weeks depending on sample type, number of conditions, and whether quantitative multiplexing is required.